Arthur Hayes, co-founder and CIO of Maelstrom, stated that Bitcoin's weakness is likely to continue until the Federal Reserve or commercial banks expand their balance sheets. He explained that liquidity in USD is recharging but Bitcoin will remain under pressure until this balance-sheet growth happens. Hayes highlighted that the Fed's purchase of Treasury securities adds reserves to banks, while commercial banks create deposits through lending or asset purchases. He did not specify which banks or the timeline for this growth, nor confirmed that balance-sheet expansion has started. This view reflects market expectations rather than policy or confirmed lending increases.
Arthur Hayes and Bitcoin's outlook provide context for cryptocurrency trends on Pluang. For readers following crypto, here is Pluang's market snapshot as of Nov 05, 2026 00:31 WIB: 45 of 50 major cryptocurrencies rose today. Notable movers include XNO at Rp6.028 (+4.44%), THETA at Rp2.851 (+4.43%), and UNI at Rp138.430 (+4.33%).
Goldman Sachs Group, Inc. disclosed that it briefly held a combined stake exceeding 3% in Ontex Group NV shares as of October 27, 2026, with 566,115 voting rights and 1,965,157 financial instruments. However, by October 28, 2026, their combined posit...
BNP Paribas announced its monthly declaration of voting rights and shares as of October 31, 2026. The bank reported a total of 1,101,600,607 shares and an equal number of voting rights. This update is part of regulatory compliance under French commer...
Ontex disclosed that Goldman Sachs Group, Inc. crossed the 3% ownership threshold in Ontex shares on October 27, 2026, holding a combined total of 3.07% including voting rights and financial instruments. However, the next day, October 28, 2026, Goldm...
Neion Bio has appointed John A. Maga, Ph.D., as Head of Biologics and CMC to lead the development of biologic medicines using its Raptor platform, which produces proteins in transgenic chicken eggs. Maga brings over 25 years of biopharmaceutical expe...
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
